2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
63
Breast Neoplasms
28
Neoplasms
5
Neoplasm Metastasis
3
Leiomyoma
3
Cardiovascular Diseases
3
Polycystic Ovary Syndrome
2
Neoplasms by Site
2
Endometrial Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Stage II Prostate Adenocarcinoma
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sarcopenia
1
Salivary Gland Neoplasms
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Metastatic Neuroendocrine Prostate Cancer
1
Interventions
Paclitaxel
11
Carboplatin
8
Radiotherapy
7
Letrozole
7
Cyclophosphamide
7
Trastuzumab
5
Chemotherapy, Adjuvant
5
Doxorubicin
4
Brachytherapy
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
atamestane
3
Toremifene
3
Tamoxifen
3
Radiotherapy, Conformal
3
Magnetic Resonance Spectroscopy
3
Epirubicin
3
Docetaxel
3
Cryosurgery
3
Cisplatin
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiation
2
Lapatinib
2
Fulvestrant
2
Estrogen Receptor Modulators
2
Cryotherapy
2
Capecitabine
2
Biopsy
2
Aromatase Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ductal, Breast
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled